Please provide your email address to receive an email when new articles are posted on . The phase 2 DR:EAM clinical trial did not meet the endpoint of the percentage of patients with a two-step or ...

Eye injections are the only medication currently available to treat diabetes-related retinopathy. Modern eye injections are not painful and don’t cause many side effects. Diabetic retinopathy affects ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic ...

Please provide your email address to receive an email when new articles are posted on . EXN407 met primary endpoints of safety and tolerability and also demonstrated decreases in vascular leakage and ...

CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of ...

ZUG, Switzerland, and BOSTON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, ...

Intraretinal microvascular abnormalities (IRMAs) are abnormal branching, or dilation, of the blood vessels in the retina. It occurs as a complication of diabetic retinopathy. Diabetic retinopathy ...

Diabetic eye disease is the leading cause of blindness among people ages 40 to 60. The longer you have diabetes, the greater your likelihood of developing vision problems increases. Keeping blood ...